Sarah Cannon Research Institute

Jacksonville, Florida 32256

1 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, Progressive Metastatic Castrate Resistant Prostate Cancer

Studies at this site

• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) — Recruiting now
• Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer — Completed